ORTEXORTEX News
Tracking IVZ? Get live short interest, options flow, and signals on ORTEX.Sign up free →
IV
Trader NoteIVZ

Invesco Drops Post-Earnings as Shorts Build and Analysts Nudge Targets Higher

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 3 min readdata as of 28 Oct 2026, 19:33

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

Invesco has fallen 8% over the past month to $28.43, reported its third-quarter results on October 27, and now trades roughly 19% below the consensus analyst target, a gap that highlights the disconnect between where the Street thinks the stock belongs and where the market is taking it.

The short-interest picture has shifted since the earnings preview published here three days ago. Short interest has climbed 30% over the past month in share terms to 16.3 million shares, now representing 3.7% of the free float. The weekly pace has picked up: shares short rose another 2.5% in the past seven days. That said, the borrow market remains emphatically uncrowded. Availability is at 9,507%, meaning there are roughly 400 million shares still available to lend against the existing short position. The cost to borrow has edged up to 0.46%, a 4% rise on the week but still well within the "easy borrow" range. Options positioning has also shifted since the pre-earnings note, where the put/call ratio was running near its most call-heavy reading of the year at 0.21. It has since drifted back toward its 20-day average, now at 0.25 against a mean of 0.27. That normalisation suggests the acute pre-earnings call enthusiasm has faded, but positioning is not yet defensive.

Analyst moves around the print have been constructive on targets even where ratings have stayed flat. Barclays raised its target to $33 from $32 on October 28 while holding Equal-Weight. Morgan Stanley lifted to $32 from $31 last week, also at Equal-Weight. Those neutral ratings with modest upward nudges describe a cautious consensus: analysts are marking up numbers post-print but not rushing to upgrade. The more bullish camps, BMO Capital at Outperform with a $36 target and TD Cowen at Buy with a $38 target, see considerably more room. UBS assumed coverage earlier this month with a Buy and a $41 target. The consensus mean sits at $35.07, roughly 23% above the current price. On valuation, the stock trades at 9 times earnings and just 0.88 times book, multiples that have been compressing over the past month as the share price has weakened faster than estimate revisions.

The activist angle remains on the register. Nelson Peltz last disclosed a Schedule 13D/A position of 4.62% as of May 2025. As always with 13D/G filings, that stake is as-last-disclosed around the 5% threshold, and a holder who drops below that level is not obliged to file again. There has been no new filing since May, so the position's current size is unknown. Among institutional holders, BlackRock holds 8.8% and Vanguard Capital Management 6.9%, both adding shares in the most recent reporting period. Millennium Management was a meaningful seller in the June quarter, cutting its position by roughly 6 million shares to 3.6% of the company. Insider activity over the past 90 days has been net negative, with $7.2 million more sold than bought on an open-market basis, led by senior managing directors trimming in early September when the stock was trading above $32. The CFO sold $1 million in early September as well, none of it under a pre-arranged 10b5-1 plan.

Retail attention has ticked up around the earnings event. Wikipedia page views for Invesco are running at a z-score of 1.5 relative to the past 90 days, suggesting above-average interest for the name right now. That dataset carries no verified lead relationship to Invesco's reported figures, so it is colour rather than a signal on the fundamental trajectory.

Peers had a notably divergent week. ARES rose 5% and STT gained 2.6%, while BEN was nearly flat and WT slipped 1.8%. Invesco's 1.2% weekly decline puts it in the middle of the peer pack in price terms but stands out against the alternative asset managers, which are clearly benefiting from a different sentiment backdrop than traditional active managers.

The next scheduled earnings event is January 26, 2027, giving the market 90 days to weigh whether the post-print short building, at a modest absolute level but at a quickening pace, reflects a genuine deterioration in the flow story or simply positioning against a name that has already underperformed peers with more momentum.

Stocks in this article

See the live data behind this article on ORTEX.

Open IVZ on ORTEX →

How this article was generated

Generated
28 Oct 2026, 19:42
Data as of
28 Oct 2026, 19:33
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt DataPrevious Mi Articles

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.